Ferndale Pharmaceuticals has acquired 30% of Aesthetic Technology shares in a joint commercial venture. Aesthetic Technology is the developer and manufacturer of the Dermalux LED phototherapy systems, whilst Ferndale Pharmaceuticals is a specialty dermatology company.
AesthetiCare has been announced as the exclusive UK distributor for all Dermalux systems, commencing September 1, 2014. Aesthetic Technology Ltd, creators of Dermalux LED systems, announced the partnership with AesthetiCare ahead of the launch of their new Tri Wave Portable system. Huw Anthony, managing director of Aesthetic Technology, said, “Our business has enjoyed significant growth over the past couple of years with Dermalux LED systems now installed in over 170 clinics throughout the UK and also a number overseas. With the imminent launch of our brand new Tri Wave Portable system and further exciting developments to come over the next couple of years we felt the need to strengthen our position by partnering with a forward thinking and respected company within the industry.
Give your self the edge with Cosmetic News Expo Business Workshops, located in the main exhibition hall.
Ferndale Pharmaceuticals Ltd, specialists in evidence based dermatological medical-devices, pharmaceuticals and dermo-cosmetics, have divested their OTC pharmacy brands, the acne treatment Quinoderm® and scalp treatment Ceanel® to Alliance Pharmaceuticals Ltd a wholly owned subsidiary of speciality pharmaceutical company Alliance Pharma plc (AIM: APH)Roger Bloxham manageing director of Ferndale Pharmaceuticals Ltd said; “The divestment of these brands further strengthens our balance-sheet and strategically it increases the focus on our core and rapidly growing AesthetiCare® business division and our niche hospital business. It also demonstrates the progress made in these areas and will help us further improve the service we provide to our valued customers and business partners.”